Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods
- PMID: 31042009
- DOI: 10.1002/jcp.28768
Evaluation of cytokeratin 19 as a prognostic tumoral and metastatic marker with focus on improved detection methods
Abstract
In the last few years, there has been a growing interest in Cytokeratin 19 (CK19) studies in the cancer research field. CK19 belongs to the Type I CKs, serves as a useful research tool in prognosis, diagnosis, and management of the tumors. In this paper, we dissect the metastatic potential of CK19, its relation with cancer stem cells and retinal epithelial cells behavior, its application as a tumor marker and its role among 30 cancers such as thyroid, thoracic, lung, pancreatic, cervical, colorectal, and so forth. CK19 expressed in several cancer types because of its metastatic potential. This paper also presents modified detection methods of CK19 in disseminated tumor cells.
Keywords: Cytokeratin 19; biomarker; disseminated tumor cells; neoplasm diagnosis; neoplasm prognosis.
© 2019 Wiley Periodicals, Inc.
Similar articles
-
Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors.Hum Pathol. 2021 Sep;115:19-36. doi: 10.1016/j.humpath.2021.05.012. Epub 2021 Jun 6. Hum Pathol. 2021. PMID: 34102222
-
CK7/CK19 index: A potential prognostic factor for postoperative intrahepatic cholangiocarcinoma patients.J Surg Oncol. 2018 Jun;117(7):1531-1539. doi: 10.1002/jso.25027. Epub 2018 Mar 7. J Surg Oncol. 2018. PMID: 29513894
-
Cytokeratin 19 expression in intrathoracic neoplasms: First study utilizing cellblocks, evaluating the role of a rarely used cytokeratin for lung cancers.Diagn Cytopathol. 2022 Mar;50(3):105-111. doi: 10.1002/dc.24927. Epub 2022 Jan 4. Diagn Cytopathol. 2022. PMID: 34981674
-
The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver.Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):9-15. doi: 10.1097/PAI.0b013e3181ad36ea. Appl Immunohistochem Mol Morphol. 2010. PMID: 19956064 Review.
-
CD44 and EpCAM: cancer-initiating cell markers.Curr Mol Med. 2008 Dec;8(8):784-804. doi: 10.2174/156652408786733667. Curr Mol Med. 2008. PMID: 19075676 Review.
Cited by
-
Prognostic Significance of Lymph Node Examination by the OSNA Method in Lung Cancer Patients-Comparison with the Standard Histopathological Procedure.Cells. 2020 Dec 4;9(12):2611. doi: 10.3390/cells9122611. Cells. 2020. PMID: 33291819 Free PMC article.
-
Comparative Immunohistochemical Analysis of Craniopharyngioma and Ameloblastoma: Insights into Odontogenic Differentiation.Diagnostics (Basel). 2024 Oct 17;14(20):2315. doi: 10.3390/diagnostics14202315. Diagnostics (Basel). 2024. PMID: 39451638 Free PMC article.
-
Quantitative CK19 biomarker detection in breast cancer cell lines.J Med Life. 2022 Feb;15(2):188-195. doi: 10.25122/jml-2021-1101. J Med Life. 2022. PMID: 35419102 Free PMC article.
-
Preoperative prediction of cytokeratin-19 expression for hepatocellular carcinoma using T1 mapping on gadoxetic acid-enhanced MRI combined with diffusion-weighted imaging and clinical indicators.Front Oncol. 2023 Jan 19;12:1068231. doi: 10.3389/fonc.2022.1068231. eCollection 2022. Front Oncol. 2023. PMID: 36741705 Free PMC article.
-
Enhanced Analytical Performance in CYFRA 21-1 Detection Using Lateral Flow Assay with Magnetic Bioconjugates: Integration and Comparison of Magnetic and Optical Registration.Biosensors (Basel). 2024 Dec 11;14(12):607. doi: 10.3390/bios14120607. Biosensors (Basel). 2024. PMID: 39727872 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous